On April 9, 2019, Shenyang Hongqi Pharmaceutical Co., Ltd. ("Hongqi Pharmaceutical"), a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharmaceutical"), received a certificate from the State Drug Administration Regarding the "Approval for Drug Supplement Application" (Lot Number: 2019B02684) for isoniazid tablets (specification: 0.1g), the drug passed the consistency evaluation of generic drugs.

The announcement shows that the drug is mainly used in combination with other anti-tuberculosis drugs and is suitable for the treatment of various types of tuberculosis. In 2018, the sales of Shenyang Hongqi's drug in China (excluding Hong Kong, Macao and Taiwan regions, the same below) were approximately RMB 29.09 million (unaudited). According to the latest data from IQVIA, in 2018, the sales of isoniazid tablets in China were approximately RMB 94.36 million. As of March 2019, the Group (that is, the company and its holding subsidiaries/units) has invested approximately RMB4.9 million in research and development (unaudited) for the consistency evaluation of the drug at this stage. The drug has passed the consistency evaluation of generic drugs, which is conducive to its market sales.

Hongqi Pharmaceutical currently has three varieties that have passed the consistency evaluation of generic drugs, namely pyrazinamide tablets (specifications: 0.25g, 0.5g), 0.3g rifampicin capsules, and 0.1g isoniazid tablets. As a subsidiary of Fosun Pharmaceuticals, Hongqi Pharmaceuticals has always taken independent innovation as the driving force for corporate development, and continued to improve the drug R&D and innovation system of “combination of imitation and innovation”. At the same time, it has been conducting drug consistency studies in strict accordance with national requirements to improve drug performance. Safety and effectiveness, to ensure the safety and effectiveness of drugs used by the people, and to help the country achieve the goal of ending tuberculosis by 2035 as soon as possible.